Nilotinib induces ER stress and cell death in H9c2 cells

D Lekes1, I Szadvari, O Krizanova

  • 1Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. babula@med.muni.cz.

Physiological Research
|December 24, 2016
PubMed

Insights

Nilotinib, a tyrosine kinase inhibitor, causes cardiotoxicity by impairing mitochondrial function and inducing endoplasmic reticulum stress and apoptosis in H9c2 cells. This suggests potential risks when combined with other ER-targeting drugs.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Toxicology

Background:

  • Tyrosine kinase inhibitors (TKIs) are novel anticancer drugs targeting specific cellular pathways.
  • Nilotinib, imatinib, and ponatinib are TKIs known to cause cardiotoxic and vascular effects.
  • Chronic myeloid leukemia (CML) is a malignancy where TKIs are commonly used.

Purpose of the Study:

  • To investigate the potential cardiotoxicity of nilotinib.
  • To elucidate the role of endoplasmic reticulum (ER) stress and apoptosis in nilotinib-induced toxicity.
  • To utilize H9c2 cells as a relevant cell model for studying nilotinib's effects.

Main Methods:

  • Utilized H9c2 cells as a cellular model for cardiotoxicity assessment.
  • Employed a complex approach to study ER stress and apoptosis.
  • Assessed mitochondrial function and reactive oxygen species (ROS) formation.
  • Investigated nilotinib's cytotoxic effects at clinically relevant concentrations.

Main Results:

  • Nilotinib impaired mitochondrial function in H9c2 cells.
  • Clinically relevant concentrations of nilotinib induced reactive oxygen species (ROS) formation.
  • Nilotinib was shown to induce endoplasmic reticulum (ER) stress.
  • These cellular events led to apoptotic cell death, contributing to nilotinib's cytotoxic effect.

Conclusions:

  • Nilotinib exhibits cardiotoxicity through mechanisms involving mitochondrial dysfunction, ROS production, and ER stress, culminating in apoptosis.
  • The induction of ER stress by nilotinib may have implications for co-treatment strategies with drugs affecting ER function.
  • Further research is warranted to explore the interaction of nilotinib with other pharmaceuticals, particularly those impacting ER and ER stress pathways.